Clinical Cancer Research · 2011 · 110 citations · 23 references
Life SciencesGeneticsOncologyCancer GeneticsMedical GeneticsPharmacogeneticsCancer GenomicsCancer Survival AnalysisGenome-wide Association StudiesGermline Cancer PredispositionGermline Cancer SusceptibilityPancreatic CancerGemcitabine PharmacogenomicsGenome-wide Association Study DesignGermline MutationsLinkage Disequilibrium ModelingPharmacogenomic ImplicationsPolymorphism Linkage DisequilibriumSingle-nucleotide PolymorphismsSnp Heritability
BACKGROUND AND AIMS: Cancer and Leukemia Group B 80303 was a randomized, phase III study in patients with advanced pancreatic cancer treated with gemcitabine plus either bevacizumab or placebo. We prospectively collected germline DNA and conducted a genome-wide association study (GWAS) using overall survival (OS) as the endpoint. EXPERIMENTAL DESIGN: DNA from 351 patients was genotyped for more than 550,000 single-nucleotide polymorphisms (SNP). Associations between OS and SNPs were investigated using the log-linear 2-way multiplicative Cox proportional hazards model. The subset of 294 genetically European patients was used for the primary analysis. RESULTS: A nonsynonymous SNP in interleukin (IL)17F (rs763780, H161R) and an intronic SNP in strong linkage disequilibrium (rs7771466) were associated with OS using genome-wide criteria (P ≤ 10(-7)). Median OS was significantly shorter (P = 2.61 × 10(-8)) for the rs763780 heterozygotes [3.1 months; 95% confidence interval (CI), 2.3-4.3] than for the patients without this variant (6.8 months; 95% CI, 5.8-7.3). After adjustment by stratification factors, the P value for the association was 9.51 × 10(-7). CONCLUSIONS: The variant 161R form of IL-17F is a natural antagonist of the antiangiogenic effects of wild-type 161H IL-17F, and angiogenesis may play an important role in the metastatic spread of pancreatic cancer. In this preliminary study, we hypothesize that the angiogenetic potential of pancreatic cancers in patients with variant IL-17F is higher than that of tumors in patients with wild-type IL-17F, conferring worse prognosis. This exploratory GWAS may provide the foundation for testing the biology and clinical effects of novel genes and their heritable variants through mechanistic and confirmatory studies in pancreatic cancer.
23
Principal components analysis corrects for stratification in genome-wide association studies
Alkes L. Price, Nick J. Patterson, Robert M. Plenge et al. · Nature Genetics · 2006 · 10.7K citations
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
The Genomic Landscapes of Human Breast and Colorectal Cancers
Laura D. Wood, D. Williams Parsons, Siân Jones et al. · Science · 2007 · 2.8K citations
Hedy L. Kindler, Donna Niedzwiecki, Donna Hollis et al. · Journal of Clinical Oncology · 2010 · 842 citations · Full text
Medicine, Oncology, Pharmacotherapy +11